Navigation Links
Valtech Cardio Ltd. Completes $17.8 Million in Series B Financing
Date:2/2/2010

OR YEHUDA, Israel, Feb. 2 /PRNewswire/ -- Valtech Cardio Ltd. announced today that new and existing investors (OXO Capital Valve Ventures LLC, NGN Biomed Opportunity II, L.P., and Peregrine VC Investments II, L.P.) recently completed a Series B financing of $17.8 million.

Valtech Cardio Ltd. (Valtech) is engaged in development of a portfolio of minimally-invasive surgical and transcatheter mitral valve repair and replacement technologies designed to correct or significantly improve mitral valve function in ways that reduce or eliminate mitral regurgitation (MR).  MR is a serious heart disorder characterized by incomplete closure of the mitral valve.  The valve leakage (from the left ventricle into the left atrium), often called regurgitation, reduces the amount of blood that is pumped out of the heart during each contraction and is associated with other serious medical conditions, including atrial fibrillation.  MR is believed to be the most common form of valvular heart disease.

"The enthusiastic support from our investor group provides us with the capital necessary to complete development and initial clinical evaluation of several products designed to dramatically improve mitral valve function," said Amir Gross, Founder and Chief Operating Officer of Valtech.  "The Valtech team is focused on improved annuloplasty and chordal repair technologies that will help physicians more effectively treat their patients undergoing surgical (open and minimally-invasive) and percutaneous transcatheter mitral valve repair procedures," Gross commented.

"The medical community has clearly articulated the need for advanced mitral valve repair and replacement solutions," said Lawrence C. Best, Executive Chairman of the Board.  "The mitral valve repair/replacement market appears to be primed for rapid adoption of advanced solutions that address the needs of patients and physicians.  Such product offerings should result in significant new growth opportunities in the coming years," Mr. Best added.

Valtech Cardio Ltd. is a privately held medical device company, based in Or Yehuda, Israel with a U.S. office in Waltham, Ma., committed to the development and commercialization of therapies for the millions of patients afflicted with mitral valve disorders.

SOURCE Valtech Cardio Ltd.


'/>"/>
SOURCE Valtech Cardio Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
8. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Cardiologists Tackle Next Frontier in Cardiovascular Disease
11. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):